Dogmas & Controversies in Hematologic Malignancies: Los Angeles 2026
Accreditation: 10.50 Nursing Contact Hours | 10.50 ACPE Pharmacy | 10.50 ABIM MOC II | 10.50 AMA PRA Category 1 Credit™
Venue: Sonesta Redondo Beach & Marina, 300 North Harbor Drive, Redondo Beach, CA, United States
Official conference page for Dogmas & Controversies in Hematologic Malignancies: Los Angeles 2026. https://binaytara.org/projects/conferences/dogmas-controversies-in-hematologic-malignancies-los-angeles-2026
About Dogmas & Controversies in Hematologic Malignancies: Los Angeles 2026
Overview
Trusted by Thousands of Attendees
Across Our Events
Faculty and committee
Conference program and agenda
Our Agenda
Day 1: Friday, February 27th, 2026
All timings are in Pacific Time (PDT, GMT-07:00) time.
01:30 PM - 01:50 PM
Plenary Lecture – Brian Sworder, MD, MD, PhD, PhD
01:50 PM - 02:00 PM
Q&A
Session Chair: Matthew Mei, MD
02:00 PM - 02:15 PM
CLL - How to approach cases refractory to both a covalent BTKi and a BCL2 Inhibitor – Matthew J. Cortese, MD, MPH
02:15 PM - 02:30 PM
Have we solved HL? What are the unmet needs in 2025? – Harsh Shah, DO
02:30 PM - 02:45 PM
Update in R/R MZL – Matthew Mei, MD
02:45 PM - 03:15 PM
Case-Based Panel Discussion – Lihong Wu, MD
Session Chair: Vinod Pullarkat, MD; Brian A Jonas
03:45 PM - 04:00 PM
Induction for acute myeloid leukemia: Does anyone still need 7+ 3 ? – Brian A Jonas
04:00 PM - 04:15 PM
Adding targeted agents to AML therapy backbone – Amanda Blackmon, DO
04:15 PM - 04:30 PM
Chemotherapy or chemotherapy free : Treatment of Philadelphia positive ALL – Tamer Othman, MD
04:30 PM - 04:45 PM
Who needs transplant for ALL in CR1 : Genetics vs MRD – Vinod Pullarkat, MD
04:45 PM - 05:15 PM
Case-Based Panel Discussion – Robert Matthew Carroll, MD
Day 2: Saturday, February 28th, 2026
Conference Chair: Justin Ryan Marquart, MBA
Session Chair: Jonathan L Kaufman, MD; Michael Rosenzweig, MD
08:15 AM - 08:30 AM
Newly Diagnosed TI - Optimal Treatment in 2026 – Which regimen and for how long ? – Michael Rosenzweig, MD
08:30 AM - 08:50 AM
Debate: Frontline TE in MM
08:30 AM - 08:40 AM
MRD stands for Make the Right Decision on Transplant – Aaron S Rosenberg, MD
08:40 AM - 08:50 AM
MRD stands for DON’T Make the wRong Decision regarding Upfront Transplant – Jodi Lipof, MD
08:50 AM - 09:05 AM
Optimal Maintenance - Which agents for SR/HR - MRD Guided? – Jonathan L Kaufman, MD
09:05 AM - 09:20 AM
Evaluation and Treatment of the Frail Patient – J Christine Ye, MD
09:20 AM - 09:35 AM
Triplets and ADCs – When and How to Sequence in RRMM – Sarah S Lee, MD, MD
09:35 AM - 09:45 AM
Case Presentation – Kwan-Keat Ang, MD, MD
Session Chair: Vinod Pullarkat, MD; Jerald Radich, MD
10:15 AM - 10:30 AM
Prognostication of MDS and timing of stem cell transplant – Wanxing Chai-Ho, MD
10:30 AM - 10:45 AM
MRD monitoring in AML. How and when? – Jerald Radich, MD
10:45 AM - 11:00 AM
Treatment of aplastic anemia in adults: Choosing IST vs transplant – Ryotaro Nakamura, MD
11:00 AM - 11:15 AM
MPN: Do available drugs provide survival benefit? – Angela Fleischman, MD, MD, PhD
11:15 AM - 11:45 AM
Case-Based Panel Discussion – Idoroenyi Amanam, MD; Saro Kasparian
11:45 AM - 11:55 AM
IDH Inhibitors – Diana Tran Samuels, PharmD, PharmD
11:55 AM - 12:05 PM
Menin Inhibitors – Maria Motta, DNP, ARNP
12:05 PM - 12:15 PM
FLT3 Inhibitors – Gabriel Park, PharmD
12:15 PM - 12:30 PM
Case-Based Panel Discussion – Maria Motta, DNP, ARNP; Gabriel Park, PharmD; Diana Tran Samuels, PharmD, PharmD